SAGE-324

SAGE-324 is an experimental drug developed by Sage Therapeutics, a biopharmaceutical company based in Cambridge, Massachusetts. It is currently in clinical trials for the treatment of essential tremor, a neurological disorder characterized by involuntary and rhythmic shaking.

Overview

SAGE-324 is a next-generation positive allosteric modulator of GABA receptors, the primary inhibitory neurotransmitter in the brain. It is designed to enhance the function of synaptic and extrasynaptic GABA receptors. The drug is being developed to address conditions associated with excessive neuronal activity, such as essential tremor.

Clinical Trials

Sage Therapeutics has initiated a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAGE-324 in patients with essential tremor. The primary endpoint of the study is the change from baseline in the TETRAS Performance Subscale Score, a validated scale for assessing essential tremor.

Potential Impact

Essential tremor is one of the most common neurological disorders, but treatment options are limited. If successful, SAGE-324 could provide a new therapeutic option for patients suffering from this debilitating condition.

See Also

• Sage Therapeutics
• Essential tremor
• Clinical trial
• GABA receptor

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• 
  SAGE-324